Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
07/2003
07/31/2003WO2003062225A1 Pyrimidine derivatives as rho-kinase inhibitors
07/31/2003WO2003062209A2 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
07/31/2003WO2003062205A1 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
07/31/2003WO2003062191A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
07/31/2003WO2003062189A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
07/31/2003WO2003061757A1 Transdermal/transmucosal preparations for electroporation
07/31/2003WO2003061698A1 6-fluorobicyclo[3.1.0]hexane derivatives
07/31/2003WO2003061688A1 Novel analgesics
07/31/2003WO2003061685A1 Therapeutic application of g-csf, gm-csf and scf
07/31/2003WO2003061678A1 Sedative materials and treatments
07/31/2003WO2003061673A1 Use of phosphorous dendrimers as medicaments.
07/31/2003WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies
07/31/2003WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases
07/31/2003WO2003061661A1 Orally dispersible pharmaceutical piribedil composition
07/31/2003WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators
07/31/2003WO2003061658A1 Sigma receptor binder containing indanone derivative
07/31/2003WO2003061656A1 Pharmaceutical composition and method for treating disorders of the central nervous system
07/31/2003WO2003061655A1 2-aminothiazole allosteric enhancers of a1 adenosine receptors
07/31/2003WO2003061654A1 Pramipexole for the treatment of hiv dementia
07/31/2003WO2003061651A1 Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
07/31/2003WO2003061648A1 Use of cholinesterase antagonists to treat insulin resistance
07/31/2003WO2003061644A1 Orodispersible pharmaceutical composition comprising agomelatine
07/31/2003WO2003061642A1 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias
07/31/2003WO2003061634A1 Sustained release pharmaceutical composition
07/31/2003WO2003061632A1 Method of treatment of a patient requiring analgesia
07/31/2003WO2003061626A1 Polymeric gel system for the controlled delivery of codrugs
07/31/2003WO2003061620A2 Peptide-carrying bodies for immune response
07/31/2003WO2003061573A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
07/31/2003WO2003061563A2 Method of preparing delta-9 tetrahydrocannabinol
07/31/2003WO2003061555A2 West nile vaccine
07/31/2003WO2003057698A3 Spiroazacyclic compounds as monoamine receptor modulators
07/31/2003WO2003053429A3 2-indanylamino derivatives for the therapy of chronic pain
07/31/2003WO2003047516A3 Pyrimidine compounds
07/31/2003WO2003045978A3 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
07/31/2003WO2003041649A3 Cyanoalkylamino derivatives as protease inhibitors
07/31/2003WO2003040339A3 Antisense modulation of purinoreceptor p2x¿3?
07/31/2003WO2003027061A3 Muscarinic agonists
07/31/2003WO2003020702A9 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
07/31/2003WO2003010243A3 Multipotent stem cells from peripheral tissues and uses thereof
07/31/2003WO2003006016A3 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
07/31/2003WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
07/31/2003WO2002101005A3 A g-protein coupled receptor and uses therefor
07/31/2003WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels
07/31/2003WO2002094767A3 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
07/31/2003WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
07/31/2003WO2002092065A3 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
07/31/2003WO2002083729A3 Polypeptides derived from amyloid precursor peptide (app) and their uses
07/31/2003WO2002068421A3 Tricyclic compounds and their analogs as inhibitors of cytokine signaling
07/31/2003WO2002064627A3 Crystallization of igf-1
07/31/2003WO2002062762A3 Potassium channel openers
07/31/2003WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
07/31/2003WO2002047730A3 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
07/31/2003WO2002040471A9 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
07/31/2003WO2002036169A3 Methods and compositions for enhanced delivery of bioactive molecules
07/31/2003WO2002030863A3 Ether compounds and compositions for cholesterol management and related uses
07/31/2003WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
07/31/2003WO2002024909A3 Receptor nucleic acids and polypeptides
07/31/2003WO2002018548A3 Tyrosine hydroxylase 5' control elements and uses thereof
07/31/2003WO2002012286A3 Stress proteins and peptides and methods of use thereof
07/31/2003WO2001085912A3 Presenilin enhancers
07/31/2003US20030144525 Conjugated aromatic compounds with a pyridine substituent
07/31/2003US20030144516 Crystalline form VII of cabergoline
07/31/2003US20030144510 Preparation of pharmaceutical salts
07/31/2003US20030144492 Anticancer agents; central nervous system disorders; antiinflammatory agents
07/31/2003US20030144357 Inhibition of glutamine synthetase; antiswelling and antiepileptic agents
07/31/2003US20030144356 Formulation
07/31/2003US20030144347 Method for treating autoimmune disease
07/31/2003US20030144337 Pyrazole-derived kinase inhibitors and uses thereof
07/31/2003US20030144334 Cyclopentabenzofuran derivatives and their use
07/31/2003US20030144332 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
07/31/2003US20030144331 p53 inhibitors and therapeutic use of the same
07/31/2003US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4
07/31/2003US20030144326 Cyclic amine phenyl beta-3 adrenergic receptor agonists
07/31/2003US20030144323 Phenylalkynes
07/31/2003US20030144322 Analogs of cocaine
07/31/2003US20030144316 Remedies
07/31/2003US20030144309 Inhibitors of Src and other protein kinases
07/31/2003US20030144302 Process for making substituted pyrazoles
07/31/2003US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
07/31/2003US20030144299 Method of treating depression with delta receptor agonist compounds
07/31/2003US20030144295 A synergistic antiischemic mixture of a tissue plasminogen activator, e.g. alteplase, pamiteplase, and zonampanel(7-imidazol-1-yl-6-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin -1-yl acetic acid for strokes or cerebral infarctions
07/31/2003US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives
07/31/2003US20030144291 Substituted indan derivatives
07/31/2003US20030144290 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives
07/31/2003US20030144289 Dopamine and serotonin reuptake antagonists, used for the prophylaxis of drug abuse or dependence, neurodegenerative diseases or as antidepressants
07/31/2003US20030144288 Sulfur compounds such as 4-fluoro-N-(4-methoxy-7-(tetrahydro-pyran-4-yl)-benzothiazol-2-yl) -benzamide, used as preferential adenosine receptor ligands for the prophylaxis of neurodegenerative disorders
07/31/2003US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis
07/31/2003US20030144283 Amide substituted imidazoquinolines
07/31/2003US20030144281 Substituted benzimidazole compounds
07/31/2003US20030144280 Heterocyclic imines, used as cyclooxygenase inhibitors, administered as inflammatory and pain relievers in disorders such as arthritis, neurodegeneration or cancer in mammals
07/31/2003US20030144279 5-Heterocyclo-pyrazoles
07/31/2003US20030144275 Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis
07/31/2003US20030144271 Methods for the treatment of substance abuse
07/31/2003US20030144270 Neurokinin receptor antagonists comprising heterocyclic amides used as antiemetics, antidepressants and/or antitussive agents
07/31/2003US20030144267 Novel compounds
07/31/2003US20030144262 Heteroaryl and heterocyclic nitrogen ring containing hydrazide compounds useful for treating neurodegenerative disorderes
07/31/2003US20030144253 Useful for treating or preventing neuronal damage associated with neurological diseases
07/31/2003US20030144247 Obtained by reacting polyalkylene glycol or a reactive derivative, a phospholipid and a drug with each other to form covalent bonds to form a delivery substance
07/31/2003US20030144234 Administering a cathepsin modulator or enzyme inhibitor, select from a mRNA or a protein; gene expression inhibition, analgesics
07/31/2003US20030144214 Alkyl amino acid derivatives useful as pharmaceutical agents
1 ... 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 ... 1833